SCHEMBL13879752

SCHEMBL13879752

CCOC(=O)c1csc(OC(=O)c2csc(NC(=O)c3csc(N)n3)n2)n1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 8/20 0.62
NPC1 O15118 6/20 0.62
ALDH1A1 P00352 3/20 0.62
MAPT P10636 2/20 0.62
MEN1 O00255 2/20 0.62
KMT2A Q03164 2/20 0.62
SMN1; SMN2 Q16637 7/20 0.57
CYP1A2 P05177 1/20 0.57
CYP2C19 P33261 1/20 0.57
TDP1 Q9NUW8 1/20 0.55
HSP90AA1 P07900 3/20 0.54
MAPK1 P28482 1/20 0.54
KDM4E B2RXH2 3/20 0.53
HPGD P15428 2/20 0.53
TSHR P16473 1/20 0.53
LMNA P02545 3/20 0.52
POLB P06746 2/20 0.52
NPSR1 Q6W5P4 1/20 0.52
HSD17B10 Q99714 1/20 0.52
EGFR P00533 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14072172 0.92 RAB9A (0.72) RAB9ANPC1ALDH1A1MAPTMEN1
SCHEMBL14543311 0.89 SMN1; SMN2 (0.60) RAB9ANPC1ALDH1A1MAPTSMN1; SMN2
SCHEMBL13879748 0.84 SMN1; SMN2 (0.54) RAB9ANPC1ALDH1A1MAPTSMN1; SMN2
SCHEMBL14072241 0.80 RAB9A (0.53) RAB9ANPC1ALDH1A1MAPTMEN1
SCHEMBL13879764 0.80 CYP1A2 (0.69) RAB9ANPC1ALDH1A1MAPTSMN1; SMN2
SCHEMBL220846 0.79 RAB9A (0.97) RAB9ANPC1ALDH1A1MAPTMEN1
Hydrochloric Acid SCHEMBL16653815 0.78 RAB9A (1.00) RAB9ANPC1ALDH1A1MAPTMEN1
Bromide SCHEMBL3048612 0.78 RAB9A (0.94) RAB9ANPC1ALDH1A1MAPTMEN1
SCHEMBL3931386 0.75 SMN1; SMN2 (0.62) RAB9ANPC1ALDH1A1MAPTSMN1; SMN2
SCHEMBL4636472 0.75 SMN1; SMN2 (0.62) RAB9ANPC1ALDH1A1MAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8637664-B2 Alkyl 4- [4- (5-oxo-2,3,5, 11a-tetrahydo-5H-pyrrolo [2, 1-c] [1,4] benzodiazepine-8-yloxy)-butyrylamino]-1H-pyrrole-2-carboxylate derivatives and related compounds for the treatment of a proliferative disease SPIROGEN SARL (CH) 2014-01-28 US disclosed
EP-1931671-B1 ALKYL 4- [4- (5-OXO-2, 3, 5, 11A-TETRAHYD0-5H-PYRR0L0 [2, 1-C][1, 4]BENZODIAZEPINE-8-YLOXY) -BUTYRYLAMINO]-1H-PYRROLE-2-CARBOXYLATE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF A PROLIFERATIVE DISEASE SPIROGEN LTD (GB) 2009-04-08 EP disclosed
US-20080214525-A1 Alkyl 4- [4- (5-Oxo-2,3,5, 11A-Tetrahydo-5H-Pyrrolo [2, 1-C] [1,4] Benzodiazepine-8-Yloxy) -Butyrylamino]-1H-Pyrrole-2-Carboxylate Derivatives and Related Compounds For the Treatment of a Proliferative Disease SPIROGEN LIMITED (GB) 2008-09-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080214525-A1 Alkyl 4- [4- (5-Oxo-2,3,5, 11A-Tetrahydo-5H-Pyrrolo [2, 1-C] [1,4] Benzodiazepine-8-Yloxy) -Butyrylamino]-1H-Pyrrole-2-Carboxylate Derivatives and Related Compounds For the Treatment of a Proliferative Disease CCNY, NR0B1, CNR1 RAB9A 2266/4885NPC1 1323/4885ALDH1A1 2826/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.